Biomarker Clinical Trial
Official title:
Study of Systemic Impact of Trace Elements Release by Implantable Medical Devices. Identification of Biomarkers of Systemic Inflammation
The main objective of this study is to evaluate the systemic impact of salting out of trace elements (TE) by metallic and nonmetallic implantable medical devices (IMD) and in particular the immune response of the organism to these trace elements and of their target organs, and to identify circulating protein biomarkers which might indicate an evolution of inflammation caused by an IMD.
As secondary objectives, the study aims: - to establish the norms of concentrations of free TE and nanoparticles for some forty of elements (in particular Chrome, Cobalt, Nickel, Titanium, Tantalum, Zirconium, Tungsten, Gold, Silver, Mercury, Molybdenum, Strontium ...) in different materials (blood, urine, hair and the viscera), with non-IMD holder subjects, before and after mineralization of these materials (dead patients and autopsied non-IMD holder subjects and subjects before placement of IMD. - to evaluate the distribution of concentrations of metals in the same materials and in peri-prothetic environment with IMD holder subjects (dead autopsied patients), more often with no inflammatory sign, with possibility of some probably inflammatory IMD. - to evaluate the parameters of distributions of concentrations of metals in same materials (with the exception of the viscera) with living IMD holder patients, with inflammatory reaction (during revision surgery). - to define the most suitable material (accessibility, concentrations, absence of contamination) for follow-up and evolution of inflammation in order to determinate norms of studied metals concentration. - to determinate proportion between different forms of circulation: particulate form (analysis after full mineralization) or free form (analysis without mineralization, permitting measurement of free forms), trace elements in organism. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03219593 -
Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04681040 -
Risk Stratification of COVID-19 Using Urine Biomarkers
|
||
Recruiting |
NCT05372172 -
Tennessee Alzheimer's Project
|
||
Recruiting |
NCT06096766 -
the Correlation Between Ovarian Function and Serum Biomarkers
|
||
Completed |
NCT04103632 -
Screening and Diagnosing Exercise-induced Bronchoconstriction in Recreational Young Athletes (12-18 y)
|
N/A | |
Completed |
NCT01159730 -
Study to Assess the Safety and Efficacy of Multiple Doses of VB-201 on Biomarkers
|
Phase 2 | |
Completed |
NCT04507724 -
The Use of Biochemical Analyzes to Monitor the Development of Wounds
|
||
Completed |
NCT06338111 -
Can we Improve Mortality Prediction in Patients With Sepsis in the Emergency Department
|
||
Active, not recruiting |
NCT05027165 -
Prospective Evaluation of Immunological, Molecular-genetic, Image-based and Microbial Analyzes to Characterize Tumor Response and Control in Patients With Inoperable Stage III NSCLC Treated With Chemoradiotherapy Followed by Consolidation Therapy With Durvalumab
|
||
Not yet recruiting |
NCT02931136 -
Early Diagnosis and Early Treatment of Alzheimer's Disease Based on Senile Plaque Imaging
|
Phase 4 | |
Not yet recruiting |
NCT03739892 -
Biomarkers to Predict Gain From Therapy in Motor Stroke
|
N/A | |
Recruiting |
NCT03801681 -
ARrhythmias in MYocarditis
|
||
Recruiting |
NCT05372965 -
The Effects of Smoking on miRNA-223 Before-After Non-Surgical Periodontal Therapy in Patients With Stage-3, Grade-B Periodontitis
|
N/A | |
Completed |
NCT04772495 -
miRNA Biomarkers in Multiple Sclerosis
|
||
Active, not recruiting |
NCT06178692 -
Validation Study of a Serum-miRNA Signature in Glioma Patients.
|
||
Recruiting |
NCT04931537 -
Screening and Application Research of Early Diabetic Nephropathy Markers Based on Lipidomics.
|
||
Recruiting |
NCT05090410 -
Efficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate
|
Phase 3 | |
Not yet recruiting |
NCT05764356 -
Imapct of bioMarkers on Pharmacodynamics and Bleeding Risk of Direct Oral AntiCoagulants and Ticagrelor Study II
|
||
Recruiting |
NCT02201446 -
The Role of Circulating Soluble CD74 in Acute Lung Injury
|
N/A | |
Not yet recruiting |
NCT05752890 -
A Novel Biomarker for Response and Prognosis of HBV-related Hepatocellular Carcinoma
|